EE05051B1 - Fumaarhappe derivaadid kasutamiseks mitokondriaalsete haiguste ravis - Google Patents
Fumaarhappe derivaadid kasutamiseks mitokondriaalsete haiguste ravisInfo
- Publication number
- EE05051B1 EE05051B1 EEP200200333A EEP200200333A EE05051B1 EE 05051 B1 EE05051 B1 EE 05051B1 EE P200200333 A EEP200200333 A EE P200200333A EE P200200333 A EEP200200333 A EE P200200333A EE 05051 B1 EE05051 B1 EE 05051B1
- Authority
- EE
- Estonia
- Prior art keywords
- fumaric acid
- treatment
- mitochondrial diseases
- acid derivatives
- sdh
- Prior art date
Links
- 208000012268 mitochondrial disease Diseases 0.000 title abstract 3
- 150000002237 fumaric acid derivatives Chemical class 0.000 title abstract 2
- 102000019259 Succinate Dehydrogenase Human genes 0.000 abstract 4
- 108010012901 Succinate Dehydrogenase Proteins 0.000 abstract 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000000648 anti-parkinson Effects 0.000 abstract 1
- 239000000939 antiparkinson agent Substances 0.000 abstract 1
- 230000001966 cerebroprotective effect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 abstract 1
- 229960004419 dimethyl fumarate Drugs 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 210000001700 mitochondrial membrane Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 230000010627 oxidative phosphorylation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000001384 succinic acid Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10000577A DE10000577A1 (de) | 2000-01-10 | 2000-01-10 | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
| PCT/EP2000/012504 WO2001051047A1 (de) | 2000-01-10 | 2000-12-11 | Verwendung von fumarsäurederivaten zur behandlung mitochondrialer krankheiten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE200200333A EE200200333A (et) | 2003-08-15 |
| EE05051B1 true EE05051B1 (et) | 2008-08-15 |
Family
ID=7627026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200200333A EE05051B1 (et) | 2000-01-10 | 2000-12-11 | Fumaarhappe derivaadid kasutamiseks mitokondriaalsete haiguste ravis |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6858750B2 (cs) |
| EP (1) | EP1248606B1 (cs) |
| JP (1) | JP2003529556A (cs) |
| CN (1) | CN1433303A (cs) |
| AT (1) | ATE329590T1 (cs) |
| AU (1) | AU772409B2 (cs) |
| BG (1) | BG65468B1 (cs) |
| BR (1) | BR0016935A (cs) |
| CA (1) | CA2390886C (cs) |
| CY (1) | CY1105462T1 (cs) |
| CZ (1) | CZ303680B6 (cs) |
| DE (2) | DE10000577A1 (cs) |
| DK (1) | DK1248606T3 (cs) |
| EE (1) | EE05051B1 (cs) |
| ES (1) | ES2265367T3 (cs) |
| HU (1) | HU229138B1 (cs) |
| IL (2) | IL150516A0 (cs) |
| MX (1) | MXPA02006695A (cs) |
| NO (1) | NO326875B1 (cs) |
| NZ (1) | NZ518781A (cs) |
| PL (1) | PL223342B1 (cs) |
| PT (1) | PT1248606E (cs) |
| RS (1) | RS50185B (cs) |
| RU (1) | RU2218918C1 (cs) |
| SI (1) | SI1248606T1 (cs) |
| SK (1) | SK286719B6 (cs) |
| WO (1) | WO2001051047A1 (cs) |
| ZA (1) | ZA200205481B (cs) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| DE10000577A1 (de) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
| DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| AU2002219236B2 (en) * | 2001-01-12 | 2006-02-09 | Biogen International Gmbh | Fumaric acid amides |
| DE10217314A1 (de) * | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
| US7224426B2 (en) * | 2002-07-31 | 2007-05-29 | Dai Nippon Printing Co., Ltd. | Optical element |
| DE602004010531T2 (de) * | 2003-09-09 | 2008-07-03 | Fumapharm Ag | Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma |
| PT2316430E (pt) | 2004-10-08 | 2012-06-26 | Forward Pharma As | Composições farmacêuticas de libertação controlada compreendendo um éster de ácido fumárico |
| ATE455783T1 (de) * | 2005-07-07 | 2010-02-15 | Aditech Pharma Ag | Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung |
| EP1915334A2 (en) * | 2005-07-07 | 2008-04-30 | Aditech Pharma AB | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| WO2008070121A1 (en) * | 2006-12-06 | 2008-06-12 | Cornell Research Foundation, Inc. | Intermediate duration neuromuscular blocking agents and antagonists thereof |
| EP3135282A1 (en) * | 2007-02-08 | 2017-03-01 | Biogen MA Inc. | Neuroprotection in demyelinating diseases |
| HRP20220902T3 (hr) | 2007-02-08 | 2022-10-14 | Biogen Ma Inc. | Pripravci i njihova upotreba u liječenju multiple skleroze |
| PL2334378T3 (pl) | 2008-08-19 | 2014-09-30 | Xenoport Inc | Proleki wodorofumaranu metylu, ich kompozycje farmaceutyczne i sposoby zastosowania |
| WO2010079221A1 (en) * | 2009-01-09 | 2010-07-15 | Forward Pharma A/S | Pharmaceutical composition comprising one or more fumaric acid esters |
| UA112975C2 (uk) * | 2009-01-09 | 2016-11-25 | Форвард Фарма А/С | Фармацевтичний склад, що містить в матриці, яка піддається ерозії, один або більше ефірів фумарової кислоти |
| WO2010107488A1 (en) | 2009-03-17 | 2010-09-23 | Cornell University | Reversible nondepolarizing neuromuscular blockade agents and methods for their use |
| US9220700B2 (en) | 2009-08-19 | 2015-12-29 | Cornell University | Cysteine for physiological injection |
| US20140142095A1 (en) * | 2011-04-28 | 2014-05-22 | Serket Pharma, Llc | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases |
| DK2718257T3 (en) | 2011-06-08 | 2018-02-12 | Biogen Ma Inc | PROCEDURE FOR THE PREPARATION OF HIGH PURITY Crystalline DIMETHYL FUMARATE |
| EP2782561A1 (en) | 2011-11-24 | 2014-10-01 | Synthon BV | Controlled release particles comprising dimethyl fumarate |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| CA2864040A1 (en) | 2012-02-07 | 2013-08-15 | Xenoport, Inc. | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use |
| AU2013203445C1 (en) * | 2012-02-07 | 2017-04-20 | Biogen Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
| AU2013305684B2 (en) | 2012-08-22 | 2016-11-24 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| ES2733961T3 (es) | 2012-12-21 | 2019-12-03 | Biogen Ma Inc | Derivados de fumarato sustituidos con deuterio |
| KR101814474B1 (ko) | 2013-03-14 | 2018-01-12 | 엘커메스 파마 아일랜드 리미티드 | 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도 |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
| WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| EP3041467A1 (en) | 2013-09-06 | 2016-07-13 | XenoPort, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
| WO2015127450A1 (en) | 2014-02-24 | 2015-08-27 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| WO2016061393A1 (en) | 2014-10-15 | 2016-04-21 | Xenoport, Inc. | Fumarate compounds, pharmaceutical compositions, and methods of use |
| MX382175B (es) | 2015-02-08 | 2025-03-13 | Alkermes Pharma Ireland Ltd | Composiciones de profármaco de monometilfumarato |
| DK3273951T3 (da) | 2015-03-27 | 2020-11-02 | Symbionyx Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til behandling af psoriasis |
| WO2016194004A1 (en) | 2015-06-01 | 2016-12-08 | Sun Pharmaceutical Industries Ltd. | Pharmaceutical compositions of dimethyl fumarate |
| WO2017060400A1 (en) | 2015-10-07 | 2017-04-13 | Neurovive Pharmaceutical Ab | Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions |
| IT201700087376A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| IT201700087359A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| RU2674286C1 (ru) * | 2018-03-20 | 2018-12-07 | Исмагилов Искандар Халиуллович | Средство для лечения заболевания, обусловленного нарушением окислительного стресса |
| IT201800006725A1 (it) | 2018-06-27 | 2019-12-27 | Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche | |
| IT201900002109A1 (it) | 2019-02-13 | 2020-08-13 | Professional Dietetics Spa | Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale |
| RU2742745C1 (ru) * | 2019-09-24 | 2021-02-10 | Акционерное общество "Исследовательский Институт Химического Разнообразия" | Лекарственная форма в виде капсулы, содержащая таблетки с диметилфурмаратом |
| IT202000000442A1 (it) | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3832287A (en) | 1972-03-02 | 1974-08-27 | Lilly Co Eli | Dipeptide antibiotic and method for the production thereof |
| DE2530372A1 (de) | 1975-07-08 | 1977-01-13 | Walter Dr Schweckendiek | Pharmazeutische zubereitungen zur behandlung von psoriasis |
| DE2621214C3 (de) | 1976-05-13 | 1981-11-12 | Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen | Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen |
| DE3127432A1 (de) | 1981-07-11 | 1983-02-03 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von fumarsaeuremonoester |
| US5149695A (en) | 1985-01-15 | 1992-09-22 | Speiser Peter P | Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same |
| CH664150A5 (de) | 1985-01-15 | 1988-02-15 | Peter Paul Prof Dr Speiser | Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen. |
| JPS61194020A (ja) * | 1985-02-22 | 1986-08-28 | Dai Ichi Seiyaku Co Ltd | 網膜症治療剤 |
| IL83775A (en) | 1987-09-04 | 1991-12-15 | Dexter Chemical Corp | Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis |
| US5242905A (en) | 1987-09-04 | 1993-09-07 | Dexter Chemical Corporation | Pharmaceutical compositions for the treatment of psoriasis |
| US5214196A (en) | 1987-09-04 | 1993-05-25 | Dexter Chemical Corporation | Diethyl ester of di-glycyl fumaramide |
| US5424332A (en) | 1987-10-19 | 1995-06-13 | Speiser; Peter P. | Pharmaceutical composition and process for the production thereof |
| US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| DE3834794A1 (de) | 1988-10-12 | 1990-04-19 | F Schielein | Oral zu verabreichendes mittel zur behandlung von psoriasis |
| WO1992012952A1 (en) | 1991-01-18 | 1992-08-06 | Dexter Chemical Corporation | Malic acid derivatives and compositions for the treatment of psoriasis |
| IT1251166B (it) * | 1991-08-09 | 1995-05-04 | Chiesi Farma Spa | Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono |
| WO1994028883A1 (en) | 1993-06-08 | 1994-12-22 | Brown Raymond K | Therapeutic compositions and methods of use |
| US5407772A (en) | 1993-11-30 | 1995-04-18 | Xerox Corporation | Unsaturated polyesters |
| DE69521122T2 (de) * | 1994-03-16 | 2002-03-07 | Cenes Ltd., Cambridge | 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze |
| IL110380A0 (en) | 1994-07-20 | 1994-10-21 | Agis Ind 1983 Ltd | Antiviral topical pharmaceutical compositions |
| US5589504A (en) | 1994-07-26 | 1996-12-31 | Cornell Research Foundation, Inc. | Treatment of newborn jaundice |
| DE69532039T2 (de) | 1994-08-30 | 2004-07-08 | Sankyo Co., Ltd. | Isoxazole |
| US6011000A (en) | 1995-03-03 | 2000-01-04 | Perrine; Susan P. | Compositions for the treatment of blood disorders |
| HU9502843D0 (en) | 1995-09-29 | 1995-11-28 | Livigene Ltd | Pharmaceutical composition |
| WO1997031906A1 (en) | 1996-02-27 | 1997-09-04 | Sankyo Company, Limited | Isoxazole derivatives |
| US6046180A (en) | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
| WO1997048405A1 (fr) | 1996-06-21 | 1997-12-24 | Jury Evgenievich Belyaev | Produit semi-fini permettant d'obtenir des bases de medicaments, bases de medicaments obtenues a l'aide ce dernier et variantes, et medicament faisant appel a ces bases et variantes |
| EP2298350A3 (en) | 1996-07-26 | 2011-06-08 | Susan P. Perrine | Composition comprising an inducing agent and an anti-viral agent for the treatment of viral disorders |
| WO1998027970A2 (en) | 1996-12-24 | 1998-07-02 | National Research Council Of Canada | Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals |
| US5972363A (en) | 1997-04-11 | 1999-10-26 | Rohm And Haas Company | Use of an encapsulated bioactive composition |
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| CA2306875C (en) * | 1997-10-24 | 2011-01-04 | John P. Blass | Nutritional supplement for cerebral metabolic insufficiencies |
| RU2136291C1 (ru) * | 1998-02-02 | 1999-09-10 | Российский научно-исследовательский институт гематологии и трансфузиологии | Полифункциональный кровезаменитель для лечения кровопотери и шока |
| DE19814358C2 (de) | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
| DE19839566C2 (de) * | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
| DE19848260C2 (de) | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
| RU2132187C1 (ru) * | 1998-11-12 | 1999-06-27 | Антипов Борис Геннадиевич | Способ лечения заболеваний кожи и слизистых оболочек и магнитоактивное органическое соединение железа, используемое в нем |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| DE10000577A1 (de) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
| RU2160589C1 (ru) | 2000-05-18 | 2000-12-20 | Алекс Кашлинский | Средство для снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома и способ снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома с использованием этого средства |
| WO2002002190A2 (en) * | 2000-07-05 | 2002-01-10 | Johns Hopkins School Of Medicine | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
-
2000
- 2000-01-10 DE DE10000577A patent/DE10000577A1/de not_active Withdrawn
- 2000-12-11 EE EEP200200333A patent/EE05051B1/xx not_active IP Right Cessation
- 2000-12-11 BR BR0016935-8A patent/BR0016935A/pt not_active Application Discontinuation
- 2000-12-11 JP JP2001551471A patent/JP2003529556A/ja active Pending
- 2000-12-11 CN CN00818784A patent/CN1433303A/zh active Pending
- 2000-12-11 EP EP00991160A patent/EP1248606B1/de not_active Expired - Lifetime
- 2000-12-11 CZ CZ20021522A patent/CZ303680B6/cs not_active IP Right Cessation
- 2000-12-11 HU HU0204182A patent/HU229138B1/hu not_active IP Right Cessation
- 2000-12-11 AT AT00991160T patent/ATE329590T1/de active
- 2000-12-11 IL IL15051600A patent/IL150516A0/xx active IP Right Grant
- 2000-12-11 SI SI200030869T patent/SI1248606T1/sl unknown
- 2000-12-11 DK DK00991160T patent/DK1248606T3/da active
- 2000-12-11 MX MXPA02006695A patent/MXPA02006695A/es active IP Right Grant
- 2000-12-11 ES ES00991160T patent/ES2265367T3/es not_active Expired - Lifetime
- 2000-12-11 PT PT00991160T patent/PT1248606E/pt unknown
- 2000-12-11 RU RU2002121493/15A patent/RU2218918C1/ru not_active IP Right Cessation
- 2000-12-11 DE DE50013000T patent/DE50013000D1/de not_active Expired - Lifetime
- 2000-12-11 RS YUP-514/02A patent/RS50185B/sr unknown
- 2000-12-11 CA CA002390886A patent/CA2390886C/en not_active Expired - Fee Related
- 2000-12-11 PL PL356714A patent/PL223342B1/pl unknown
- 2000-12-11 WO PCT/EP2000/012504 patent/WO2001051047A1/de not_active Ceased
- 2000-12-11 NZ NZ518781A patent/NZ518781A/en not_active IP Right Cessation
- 2000-12-11 SK SK652-2002A patent/SK286719B6/sk not_active IP Right Cessation
- 2000-12-11 AU AU31566/01A patent/AU772409B2/en not_active Ceased
- 2000-12-11 US US10/148,858 patent/US6858750B2/en not_active Expired - Lifetime
-
2002
- 2002-05-07 NO NO20022175A patent/NO326875B1/no not_active IP Right Cessation
- 2002-05-09 BG BG106685A patent/BG65468B1/bg unknown
- 2002-07-02 IL IL150516A patent/IL150516A/en not_active IP Right Cessation
- 2002-07-09 ZA ZA200205481A patent/ZA200205481B/xx unknown
-
2006
- 2006-08-11 CY CY20061101141T patent/CY1105462T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200200333A (et) | Fumaarhappe derivaatide kasutamine mitokondriaalsete haiguste raviks | |
| UA74346C2 (uk) | Похідні амінодикарбонових кислот, їх застосування та лікарський засіб | |
| BR0108452A (pt) | Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva | |
| NZ514234A (en) | N-cyanomethylamides as protease inhibitors | |
| TR200200648T2 (tr) | Farmasötik özelliklere sahip yeni dikarboksilik asit türevleri. | |
| TR199801642T2 (xx) | Tedavide faydal� olan karbamik asitlerin azabisiklik esterleri. | |
| ES2103587T3 (es) | Composiciones terapeuticas ingeribles, estables y absorbibles de nadh y de nadph. | |
| CY1107600T1 (el) | Κρεμα για τη θepαπεια δερματος τραυματισμενου απο τον ηλιο | |
| WO2003037323A3 (en) | Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction | |
| MXPA02006249A (es) | Nuevos derivados de azabiciclooctano, utiles en el tratamiento de arritmias cardiacas. | |
| ATE311866T1 (de) | Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln zur behandlung von erkrankungen rheumatischer natur | |
| DE60122917D1 (de) | Fermentative herstellung von d-p-hydroxyphenylglycin und d-phenylglycin | |
| IL163344A (en) | 2-(4-(3-cyclopentyloxy-4-difluoromethoxyphenyl)-4-cyanopiperidin-1-yl)acetic acid derivative compounds, process for their synthesis and compositions comprising the compounds as the active ingredient | |
| MY122830A (en) | Process for the preparation of (alpha)-(2-4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof | |
| DE59801192D1 (de) | Delta-aminolävulinsäure enthaltendes arzneimittel | |
| MXPA03002047A (es) | Fenilciclohexanocarboxamidas substituidas y su uso. | |
| ATE330597T1 (de) | Verwendung von fibrate zur herstellung eines arzneimittel zur behandlung von kongestiven herzversagens | |
| CY1106168T1 (el) | Συνθεση για την προληψη και/ή θepαπεια αγγειακων ασθενειων που συνισταται απο προπιονυλ l-καρνιτινη και συνενζυμο q10 | |
| NO20044555L (no) | Kombinasjonsprodukt omfattende en antikoagulant og anti-arrytmiske oksabispidener | |
| MXPA02006673A (es) | Proceso novedoso para la preparacion de alfa-(2,4-disulfufenil)-n-ter-butilnitrona y las sales farmaceuticamente aceptables de la misma. | |
| ATE129244T1 (de) | 4-((thiophen-2-carbonyl)oxy>pyrrolidin-2- carbonsäure, deren herstellung und deren verwendung als entzündungshemmendes und wundheilendes mittel. | |
| SV1994000023A (es) | Pirroles sustituidos ref. ran 4070/90 | |
| UA41037A (uk) | Препарат для лікування захворювань порожнини роту |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HE1A | Change of address | ||
| KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
| GB1A | Change in the ownership or in the address of the owner | ||
| HD1A | Correction of address | ||
| MM4A | Lapsed by not paying the annual fees |
Effective date: 20161211 |